VERAVera Therapeutics Inc - Ordinary Shares - Class A
Mkt Cap
$1.94BVolume
1.23M52W High
$51.6152W Low
$18.53PE Ratio
-8.49VERA Fundamentals
Price
$30.41Prev Close
$29.22Open
$29.7350D MA
$26.49Beta
1.00Avg. Volume
1.8MEPS (Annual)
-$2.75P/B
4.14Rev/Employee
$0.00Vera Therapeutics stock sinks following competitor’s successful trial
Investing.com -- Shares of Vera Therapeutics (NASDAQ:VERA) tumbled by 33% in premarket trading today after a Japanese competitor, Otsuka, reported positive results from a Phase 3 trial of a competing kidney disease therapy. Otsuka’s announcement indicated that its drug, sibeprenlimab, achieved a 51.2% reduction in proteinuria in the treatment of immunoglobulin A nephropathy (IgAN), surpassing the results from Vera’s own candidate, atacicept.
investing.com·5mo ago
Commit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using Options
Investors eyeing a purchase of Vera Therapeutics Inc (VERA) shares, but cautious about paying the going market price of 38.14/share, might benefit from considering selling puts among the...
Stock Options Channel·2y ago
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation BRISBANE, Calif., April 02...
Globe Newswire·2y ago
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vera Therapeutics (VERA Research Report), Tyra Bioscience (TYRA...
TipRanks Financial Blog·2y ago
Vera Therapeutics reports FY23 EPS ($2.25) vs ($3.35) last year
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentActively adding sites and...
Globe Newswire·2y ago
Vera Therapeutics (VERA, $44.19) Aroon Indicator entered an Uptrend on March 12, 2024.
Over the last three days, A.I.dvisor has detected that VERA's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...
Tickeron - Stocks·2y ago
Vera Therapeutics (VERA, $43.15) Aroon Indicator entered an Uptrend on March 11, 2024.
Over the last three days, A.I.dvisor has detected that VERA's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...
Tickeron - Stocks·2y ago
Vera Therapeutics (VERA, $44.3) Aroon Indicator entered an Uptrend on March 08, 2024.
Over the last three days, A.I.dvisor has detected that VERA's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...
Tickeron - Stocks·2y ago